5-MeO-MALT
Chemical compound
From Wikipedia, the free encyclopedia
5-MeO-MALT, also known as 5-methoxy-N-methyl-N-allyltryptamine, is a psychedelic drug of the tryptamine family related to 5-MeO-DALT.[1][2][3]
| Clinical data | |
|---|---|
| Other names | 5-Methoxy-N-methyl-N-allyltryptamine |
| Drug class | Non-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C15H20N2O |
| Molar mass | 244.338 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
5-MeO-MALT was first described in the literature in 2004.[1] It was encountered as a novel designer drug in 2014.[4][5] The drug's pharmacology was studied and described in greater detail in 2024.[6]
Use and effects
5-MeO-MALT was not included nor mentioned in Alexander Shulgin's book TiHKAL (Tryptamines I Have Known and Loved).[7]
Interactions
Pharmacology
Pharmacodynamics
The pharmacology of 5-MeO-MALT has been studied.[6] It is a potent serotonin 5-HT2A receptor agonist and produces the head-twitch response in rodents.[6] The drug also shows high affinity for the serotonin 5-HT1A receptor.[6]
Chemistry
Analogues
Analogues of 5-MeO-MALT include methylallyltryptamine (MALT), 4-HO-MALT (maltocin), 4-AcO-MALT, 5-MeO-DMT, 5-MeO-DET, 5-MeO-DPT, 5-MeO-DiPT, 5-MeO-DALT, 5-MeO-MET, 5-MeO-MPT, 5-MeO-MiPT, 5-MeO-EiPT, and 5-MeO-iPALT (ASR-3001), among others.
Society and culture
Legal status
Canada
5-MeO-MALT is not a controlled substance in Canada as of 2025.[8]
Hungary
5-MeO-MALT is illegal in Hungary.[9]
Sweden
Sweden's public health agency suggested classifying 5-MeO-MALT as a hazardous substance, on May 15, 2019.[10][11]
United States
5-MeO-MALT is not an explicitly controlled substance in the United States.[12] However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.